At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating ACI-35.030, Placebo, and 1 other intervention for Alzheimer's Disease and 6 related conditions. Completed, enrolled 57 participants across 9 sites in 4 countries.
Detailed Summary
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.
Study Details
Timeline
Interventions
Administration of a Low dose of ACI-35.030
Administration of a Medium dose of ACI-35.030
Administration of a High dose of ACI-35.030
Administration of Placebo
Administration of a Low dose of JACI-35.054
Administration of a Medium dose of JACI-35.054